England launches clinical trial for new AI-based cancer blood tests

A pioneering clinical trial has launched in England to evaluate whether general practitioners can use simple blood tests to diagnose common cancers more rapidly. Developed by the University of Birmingham, these diagnostic tests utilize artificial intelligence to identify markers for various cancers from a single blood sample and estimate the primary site of the disease within the body. The initiative aims to significantly improve patient survival rates by accelerating the identification of individuals who require urgent treatment.

The study focuses on abdominal cancers that are frequently diagnosed at advanced stages, including those of the prostate, ovaries, bowel, pancreas, stomach, and liver. At least 200 general practitioners from England's National Health Service (NHS) are participating in this global first, which seeks to address the issue of late-stage diagnosis. This development is particularly relevant for the United Kingdom, which currently reports one of the highest per capita cancer mortality rates among OECD countries. The results of this trial are expected to provide critical data on the efficacy of integrating these diagnostic tools into primary care settings.